ERBB2 and neoplasm: In first-line treatment, the combination of vinorelbine with trastuzumab and pertuzumab reached the mPFS of 14.2 months, indicated that vinorelbine plus dual anti-HER2 therapy showed successful anti-tumor activity and few adverse effects (21, 22)..